Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Travel Awards - Institute Community Support

University of Alberta

$1,000.00

Nucleolar Matrix Metalloproteinase-2 Regulates rRNA Transcription

FY 2017-18

Summary
Prior to cell division, the cell needs to duplicate its DNA, proteins and organelles so that the cell can partition evenly when it divides. Gene expression is controlled by regions on the DNA called promoters. Binding of certain proteins to DNA promoters can initiate the transcription of that gene to form RNA. Before this can occur, DNA must unravel from tightly bound histones, specialized proteins which keep the DNA compact and inaccessible to the transcription machinery. Histones are conserved proteins with specific chemical modifications on their amino acids tails. These modifications regulate DNA transcription by determining how tightly DNA is bound to the histones. After the RNA is synthesized from DNA, ribosomes are necessary to translate the RNA into protein. Matrix metalloproteinase 2 (MMP-2) is an enzyme with specialized roles in cutting other proteins inside and outside of cells. Inside cells, MMP-2 can be found in the nucleus, but its biological role there is unknown. We found that MMP-2 is enriched in the promoter region of the gene for making ribosomal proteins. We also found that MMP-2 can cut histones so that the DNA is more accessible for transcription. The involvement of MMP-2 in RNA ribosomal gene expression is an important new mechanism how intracellular MMP-2 may regulate cell function in the nucleus. This has major implications in cell division, particularly in rapidly dividing cells like cancer cells, whose growth rates were impaired by drugs which block MMP activity. This understanding may aid in the development of more selective MMP inhibitors for use as anticancer drugs.
Program
Travel Awards - Institute Community Support
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
383061
Name
Garcia-Vilas Garcia Javier A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Institute of Cancer Research
Projecttitle
Nucleolar Matrix Metalloproteinase-2 Regulates rRNA Transcription
Programtype2
Undefined
Orgnameinp2
University of Alberta
Cihramount2
$1,000
Cihrequipment2
$0
Programname2
Travel Awards - Institute Community Support
Keyworddelim
Ics Travel Awards
Abstract
Prior to cell division, the cell needs to duplicate its DNA, proteins and organelles so that the cell can partition evenly when it divides. Gene expression is controlled by regions on the DNA called promoters. Binding of certain proteins to DNA promoters can initiate the transcription of that gene to form RNA. Before this can occur, DNA must unravel from tightly bound histones, specialized proteins which keep the DNA compact and inaccessible to the transcription machinery. Histones are conserved proteins with specific chemical modifications on their amino acids tails. These modifications regulate DNA transcription by determining how tightly DNA is bound to the histones. After the RNA is synthesized from DNA, ribosomes are necessary to translate the RNA into protein. Matrix metalloproteinase 2 (MMP-2) is an enzyme with specialized roles in cutting other proteins inside and outside of cells. Inside cells, MMP-2 can be found in the nucleus, but its biological role there is unknown. We found that MMP-2 is enriched in the promoter region of the gene for making ribosomal proteins. We also found that MMP-2 can cut histones so that the DNA is more accessible for transcription. The involvement of MMP-2 in RNA ribosomal gene expression is an important new mechanism how intracellular MMP-2 may regulate cell function in the nucleus. This has major implications in cell division, particularly in rapidly dividing cells like cancer cells, whose growth rates were impaired by drugs which block MMP activity. This understanding may aid in the development of more selective MMP inhibitors for use as anticancer drugs.
Competitiondate
201802
Approvedterm2
1 yr 0 mth
Pinamesdelim
Garcia-Vilas Garcia, Javier A
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $1,000~ $0~